NCT04925986 - Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

June 22, 2023

Study Completion Date

October 30, 2023

Conditions

Carcinoma, Non-Small-Cell LungLung DiseasesLung NeoplasmsMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7PD-L1 Gene MutationAdvanced Treatment-Naïve PD-L1SitravatinibPembrolizumab

Interventions

DRUG

Sitravatinib

Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).

DRUG

Pembrolizumab

All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).

Trial Locations (1)

06520

Yale University, New Haven